SLAM
VKTX icon

Swiss Life Asset Management’s Viking Therapeutics VKTX Stock Holding History

Swiss Life Asset Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$308K Buy
7,908
+640
+9% +$20.7K ﹤0.01% 1247
2026
Q1 		$237K Buy
+7,268
New +$234K ﹤0.01% 1282

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Swiss Life Asset Management's VKTX Position: Q2 2026 in Review

Swiss Life Asset Management increased its Viking Therapeutics (VKTX) stake by 8.8% in Q2 2026, buying an estimated $20.7K and bringing the position to 7,908 shares worth $308K. The position accounts for ﹤0.01% of the portfolio, ranked #1247.

Swiss Life Asset Management first reported a position in VKTX in Q1 2026 and has held it in 2 quarters since. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Swiss Life Asset Management held 7,908 shares of Viking Therapeutics worth $308K as of Q2 2026.
  • Swiss Life Asset Management bought 640 Viking Therapeutics shares in Q2 2026, an estimated $20.7K.
  • Viking Therapeutics made up ﹤0.01% of Swiss Life Asset Management's portfolio in Q2 2026, its #1247 holding.
  • Swiss Life Asset Management first reported a position in Viking Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Swiss Life Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.